Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 4/20 | 0.65 |
| ▸ | MMP2 | P08253 | 4/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | PEPD | P12955 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2328122 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| SCHEMBL489156 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| SCHEMBL1267438 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| SCHEMBL1267008 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| SCHEMBL670494 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| SCHEMBL25181712 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| SCHEMBL1545946 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| SCHEMBL7729511 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| Hydrochloric Acid SCHEMBL1412084 | 0.98 | ANPEP (0.63) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| Hydrochloric Acid SCHEMBL2347422 | 0.98 | ANPEP (0.63) | ANPEPMMP2CYP1A2POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4540267-B1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4678238-A2 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250313578-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2025-10-09 | — | — | US | disclosed |
| EP-3752251-B1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| EP-4565590-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-12291539-B2 | KRAS G12C inhibitors | FRONTIER MEDICINES CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| CN-119866342-A | Cyclic peptides for capturing interleukin-1 beta | 默沙东有限责任公司 | 2025-04-22 | — | — | CN | disclosed |
| US-6399629-B1 | PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY | MICROCIDE PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| WO-2000001714-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| EP-0367130-B1 | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-10-02 | — | — | EP | disclosed |
| US-5514701-A | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-07 | — | — | US | disclosed |
| US-5264453-A | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-23 | — | — | US | disclosed |
| EP-0289911-B1 | PYRROLIDINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-16 | — | — | EP | disclosed |
| US-5130323-A | PYRROLIDINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-07-14 | — | — | US | disclosed |
| EP-0367130-A2 | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-09 | — | — | EP | disclosed |
| US-4916152-A | THROMBOXANE A2 ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-10 | — | — | US | disclosed |
| EP-0289911-A2 | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313578-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ANPEP 1703/4885MMP2 999/4885CYP1A2 234/4885 |
| US-12291539-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | ANPEP 4001/4885MMP2 2455/4885CYP1A2 4759/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ANPEP 4001/4885MMP2 2455/4885CYP1A2 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.